Herein, we propose an MOA for PRL3-zumab in Fig. 5d, where the interaction between the Fc domain of PRL3-zumab and FcγII/III receptors on host immune cells results in their recruitment to tumors expressing externalized PRL3 antigens to activate classical antibody-mediated tumor clearance pathways in vivo, triggering an ADCC/ADCP feedforward cascade encompassing cyclical cell killing and PRL3 leakage (“kill-and-leak” ADCC/ADCP cascade). Here, PTP4A3 is linked to neoplasm.